GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ADC Therapeutics
ADC Therapeutics is a biotechnology company specializing in antibody-drug conjugates for the treatment of cancer. Its stock price is dependent on sales of its approved drug, Zynlonta, and the clinical trial success of other candidates in its pipeline.
Share prices of companies in the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for targeted therapies for oncological diseases, primarily blood cancers. We have classified it in the "Cancer Blood" segment. The chart below shows the overall dynamics in this cutting-edge, yet high-risk, biopharmaceutical sector.
Broad Market Index - GURU.Markets
ADC Therapeutics is an oncology company developing a new class of targeted therapy—antibody-drug conjugates—for the treatment of blood cancers. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how ADCT shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ADCT - Daily change in the company's share price ADC Therapeutics
The daily price change of ADC Therapeutics, an oncology company, is a measure of its sensitivity to clinical trial results. Change_co reflects the high volatility inherent in the biotech sector. This metric is important for formulas on System.GURU.Markets that analyze companies developing targeted therapies.
Daily change in the price of a set of shares in a market segment - Cancer blood
ADC Therapeutics SA is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with ADCT's performance, which is dependent on clinical trial results, helps to assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
ADC Therapeutics is a biopharmaceutical company specializing in antibody-drug conjugates for the treatment of cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating ADC stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ADC Therapeutics
For ADC Therapeutics, the year-over-year performance is a story of bringing a new class of drugs—antibody-drug conjugates—to market for the treatment of blood cancer. Its market capitalization change over the past 12 months reflects sales successes for its approved drug, Zynlonta, and progress in clinical trials of other candidates, confirming the value of its technology platform.
Annual dynamics of market capitalization of the market segment - Cancer blood
ADC Therapeutics SA is a biotechnology company specializing in the development of a new class of targeted cancer therapies (antibody-drug conjugates). This chart shows how the market views its innovative technology, clinical trial results, and commercial potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ADC Therapeutics is a biopharmaceutical company whose stock performance is driven by the commercialization of its cancer treatments and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ADC Therapeutics
The performance of ADC Therapeutics, a biopharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its approved lymphoma drug ZYNLONTA, as well as, more importantly, news about clinical trials of new candidates in its pipeline.
Monthly dynamics of market capitalization of the market segment - Cancer blood
ADC Therapeutics SA is a biotechnology company specializing in the development of a new class of highly targeted anticancer drugs known as antibody-drug conjugates (ADCs). The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its proprietary technology and progress in clinical trials impact its future.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ADC Therapeutics develops drugs to treat blood cancer. Like many biotech companies, its stock price fluctuates wildly, responding to internal news. The chart clearly demonstrates that monthly price movements are driven by progress in clinical trials rather than macroeconomic factors that influence the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ADC Therapeutics
ADC Therapeutics is an oncology company developing antibody-drug conjugates (ADCs). Its weekly stock price is highly sensitive to clinical trial data, which will determine the future of this cutting-edge technology in the fight against cancer.
Weekly dynamics of market capitalization of the market segment - Cancer blood
ADC Therapeutics, like the entire oncology biotech sector, is extremely volatile. Weekly stock price movements in this segment often reflect broader scientific breakthroughs that influence investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ADC Therapeutics is an oncology biotech company. Its success depends on scientific breakthroughs. The chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
ADCT - Market capitalization of the company ADC Therapeutics
The ADC Therapeutics chart shows the promise and risks of developing smart cancer drugs. Its market cap reflects investor confidence in antibody-drug conjugate (ADC) technology. Its dynamics show how the market views the success of approved drugs and the potential for future developments.
ADCT - Share of the company's market capitalization ADC Therapeutics within the market segment - Cancer blood
ADC Therapeutics is a biotech company building market share by developing a new class of targeted cancer therapies—antibody-drug conjugates. Its market capitalization reflects the potential of its platform and its approved drug for the treatment of lymphoma.
Market capitalization of the market segment - Cancer blood
ADC Therapeutics is developing "smart chemotherapy." How big is this arena? The chart below shows the pulse of the blood cancer treatment sector. Its high volatility reflects both the enormous hopes for the next generation of targeted drugs and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
The ADC Therapeutics chart shows how the market is valuing "smart bomb" cancer treatment technology. This Swiss company's market capitalization is based on its antibody-drug conjugate (ADC) platform. The chart's dynamics visualize the promise and risks associated with this powerful yet toxic class of drugs.
Book value capitalization of the company, segment and market as a whole
ADCT - Book value capitalization of the company ADC Therapeutics
The book value of ADC Therapeutics, a developer of antibody-drug conjugates, is based on its tangible assets: its UK manufacturing plant, R&D laboratories, and financial reserves. The chart below shows how the company has invested in building and maintaining this sophisticated manufacturing and research base.
ADCT - Share of the company's book capitalization ADC Therapeutics within the market segment - Cancer blood
ADC Therapeutics SA is an oncology company whose strength lies in its in-house manufacturing facilities for creating its complex antibody-drug conjugates. This facility is its key strategic asset. The chart shows the company's control over this unique biotech manufacturing infrastructure.
Market segment balance sheet capitalization - Cancer blood
ADC Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. ADC focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
ADC Therapeutics' core assets are state-of-the-art manufacturing facilities in Switzerland for the production of antibody-drug conjugates (ADCs). The chart below illustrates how the company built this sophisticated manufacturing facility to fight cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ADC Therapeutics
ADC Therapeutics' assets include a unique manufacturing facility in Switzerland. The market is paying a premium for their sophisticated "smart bomb" technology for cancer treatment. The chart below shows how the market valued their scientific and manufacturing leadership.
Market to book capitalization ratio in a market segment - Cancer blood
ADC Therapeutics is developing a new class of targeted oncology drugs—antibody-drug conjugates. Its valuation is based on the potential of its platform. The chart shows a high premium to stocks, reflecting hopes for new cancer treatments.
Market to book capitalization ratio for the market as a whole
ADC Therapeutics is a biopharmaceutical company specializing in the development of antibody-drug conjugates for the treatment of cancer. Its valuation, compared to the average, is based on the success of its already approved drug and the potential of its technology platform. The market is evaluating its scientific achievements in one of the hottest areas of oncology.
Debts of the company, segment and market as a whole
ADCT - Company debts ADC Therapeutics
ADC Therapeutics is developing a new class of targeted cancer therapy—antibody-drug conjugates. This chart shows how the company is funding its costly development and commercialization of its first drug. Raising capital is necessary for clinical trials and expanding manufacturing capacity.
Market segment debts - Cancer blood
ADC Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart shows how its debt load reflects the high costs of clinical trials and commercialization of its first approved drug, as well as investments in advancing other candidates in its pipeline.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ADC Therapeutics
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates for the treatment of blood cancers. This chart shows how the company uses debt to fund its expensive research and drug launches. It helps assess its financial strength and the risks associated with drug development.
Market segment debt to market segment book capitalization - Cancer blood
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates for the treatment of cancer. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its expensive research and development in this cutting-edge field of oncology.
Debt to book value of all companies in the market
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates for cancer treatment. This is a cutting-edge but expensive field. This chart of total market debt serves as an indicator of the investment climate. It helps assess the financial system's willingness to support long-term and risky oncology developments.
P/E of the company, segment and market as a whole
P/E - ADC Therapeutics
ADC Therapeutics is a biotechnology company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart reflects the risks and potential of targeted oncology. The dynamics depend on sales of the approved drug Zynlonta and the success of other candidates in clinical trials.
P/E of the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development and commercialization of a new class of targeted anticancer drugs called antibody-drug conjugates (ADCs). This chart shows the average valuation for the oncology sector, reflecting investor expectations for this promising area of blood cancer treatment.
P/E of the market as a whole
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Its valuation depends on the commercial success of its approved drugs and research results. General market sentiment, reflected in this chart, has little impact on its business, which is driven by the specifics of the oncology market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ADC Therapeutics
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer, primarily hematological malignancies. This timeline reflects expectations for its targeted technology. This estimate is contingent on the success of its approved drug, Zynlonta, and the progress of other ADCs in clinical trials.
%20P%2FE%20ADC%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ADC-Therapeutics&v=1772631796776 "Chart of the company's future (projected) P/E ADC Therapeutics")
Future (projected) P/E of the market segment - Cancer blood
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates (ADCs)—highly targeted therapies for the treatment of blood cancers. This chart reflects investor confidence in its scientific platform. Comparing forecasts with the sector reveals how highly the market values its "smart bomb" technology for the fight against cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772631796893 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. This is one of the most promising areas in oncology. This overall risk appetite profile is key to its ability to fund expensive research in this competitive field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631796971 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ADC Therapeutics
ADC Therapeutics SA is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Its financial performance depends on sales of its approved drug and the success of clinical trials of other candidates. This chart illustrates the financial aspects of developing advanced oncology drugs.
Profit of companies in the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This technology enables the precise delivery of chemotherapy to cancer cells. The blood cancer profitability chart demonstrates how targeted therapies like ADCs are changing patient outcomes and creating new treatment standards.
Overall market profit
ADC Therapeutics is a biotechnology company specializing in the development and commercialization of a new class of targeted cancer therapies—antibody-drug conjugates (ADCs). These drugs deliver a powerful chemotherapeutic agent directly to cancer cells. The company's success reflects advances in the development of more precise and effective cancer treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ADC Therapeutics
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart shows sales expectations for its currently approved drug and the progress of other candidates in clinical trials.
%20profit%20of%20the%20company%20ADC%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ADC-Therapeutics&v=1772631797101 "Graph of future (projected) profit of the company ADC Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. This chart illustrates profitability forecasts for the biotechnology industry. It helps understand the potential of ADC technology in oncology and how the company's developments fit into overall expectations for this segment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772631797108 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
ADC Therapeutics, a biotech company, is forecasting profits based on sales of its blood cancer drugs. This chart reflects expectations for increased demand for its targeted therapy and the results of clinical trials of new candidates. This is a story in the highly specialized field of oncology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631797146 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ADC Therapeutics
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates for cancer treatment. This chart shows how investors value the revenue from its first commercial products. The multiple reflects both current sales and the potential of its technology platform.
P/S market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development and commercialization of potent antibody-drug conjugates (ADCs) for the treatment of blood cancers. Revenue is driven by sales of its products. This chart shows the average valuation in the sector, reflecting how the market values ADC technology and its application in oncology compared to other treatments.
P/S of the market as a whole
ADC Therapeutics is a biotechnology company focused on developing and commercializing a new class of targeted cancer therapies known as antibody-drug conjugates (ADCs). This graph, which displays average revenue estimates for ADC Therapeutics, helps understand how the market views its cutting-edge oncology technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ADC Therapeutics
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart shows how investors estimate the future revenue of its approved drug, Zynlonta, and the potential of other candidates in its pipeline using this promising technology.
%20P%2FS%20ADC%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ADC-Therapeutics&v=1772631797176 "The graph of the company's future (projected) P/S ADC Therapeutics")
Future (projected) P/S of the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. This chart compares market expectations for its future revenue with other companies working in the field of blood cancer treatment. The valuation reflects investor confidence in its technology platform and approved drugs.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772631797259 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
ADC Therapeutics is a biotech company developing a new class of cancer treatments—antibody-drug conjugates. Its technology enables the delivery of potent toxins directly to tumor cells. The success of its developments is part of the overall progress in targeted oncology, the expectations for which are reflected in this schedule.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631797313 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ADC Therapeutics
ADC Therapeutics is a biopharmaceutical company focused on the development and commercialization of a new class of targeted cancer therapies known as antibody-drug conjugates. This chart shows the sales revenue of its approved drugs for the treatment of hematological malignancies.
Sales of companies in the market segment - Cancer blood
ADC Therapeutics SA is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of oncological diseases, primarily blood cancers. This technology delivers chemotherapy directly to the tumor. This chart shows overall pharmaceutical sales, reflecting the potential of targeted therapy, which is becoming increasingly important in oncology.
Overall market sales
ADC Therapeutics is a biotechnology company focused on the development and commercialization of a new class of targeted cancer therapies called antibody-drug conjugates (ADCs). This overall economic activity for ADCs is important due to investment and oncology spending. A healthy economy supports the funding of expensive but promising treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ADC Therapeutics
ADC Therapeutics is a biotechnology company developing a new class of targeted cancer therapies called antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart reflects analyst expectations for the sales of its approved drug and the potential of other candidates in its pipeline.
%20sales%20of%20the%20company%20ADC%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ADC-Therapeutics&v=1772631797455 "Schedule of future (projected) sales of the company ADC Therapeutics")
Future (projected) sales of companies in the market segment - Cancer blood
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart shows projected revenue for the entire biotech sector. While it reflects overall sentiment, for ADC Therapeutics, the success of its targeted oncology drugs is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772631797469 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
ADC Therapeutics is an oncology company developing a new class of drugs—antibody-drug conjugates. Its value depends on the success of clinical trials and the commercial potential of its products. This schedule, reflecting the investment climate, affects the company's ability to attract funding for its expensive cancer research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631797536 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ADC Therapeutics
ADC Therapeutics develops and markets a new class of cancer drugs—antibody-drug conjugates. This chart reflects the economics of advanced oncology. Profitability depends on sales of its high-value drugs, which must offset the extremely high costs of research, clinical trials, and complex manufacturing.
Market segment marginality - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. This chart reflects its operational structure. It highlights the high clinical research and commercialization costs typical of companies operating at the forefront of oncology using complex technologies.
Market marginality as a whole
ADC Therapeutics is a biotechnology company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. The company's profitability depends on the success of its targeted therapies. This total market profitability chart serves as a contrast to the oncology sector, where scientific innovation aimed at precisely destroying cancer cells is key to success.
Employees in the company, segment and market as a whole
Number of employees in the company ADC Therapeutics
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This graph shows the team of scientists and clinicians. The staff dynamics reflect progress in bringing approved drugs to market and developing new candidates in this promising area of oncology.
Share of the company's employees ADC Therapeutics within the market segment - Cancer blood
This chart illustrates ADC Therapeutics' focused approach. The company's oncology team is focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of blood cancers. This team of scientists creates "smart bombs" that deliver powerful chemotherapy directly to cancer cells, minimizing damage to healthy tissue.
Number of employees in the market segment - Cancer blood
ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. This technology enables the precise delivery of chemotherapy to tumor cells. This graph illustrates how complex and science-intensive modern oncology has become, requiring the involvement of top immunologists and chemists.
Number of employees in the market as a whole
ADC Therapeutics SA is a biotechnology company developing antibody-drug conjugates for the treatment of cancer. Its value is determined by its scientific platform. This overall occupancy rate does not affect its prospects, which lie in the development of next-generation targeted therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ADC Therapeutics (ADCT)
ADC Therapeutics is a biotech company developing antibody-drug conjugates for the treatment of cancer. This chart demonstrates the high valuation of its scientific platform. The astronomical market capitalization per research employee reflects investor expectations for its innovative approach to targeted therapy, not current financial performance.
%20of%20the%20company%20ADC%20Therapeutics%20(ADCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ADC-Therapeutics-ADCT&v=1772631797821 "Chart of market capitalization per employee (in thousands of dollars) of the company ADC Therapeutics (ADCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for cancer treatment. In this cutting-edge field of oncology, the company's per-employee market cap reflects the value of its scientific platform. The chart shows the enormous value the market attributes to this targeted chemotherapy delivery technology.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772631797836 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
ADC Therapeutics is a biotech company specializing in the development of antibody-drug conjugates for the treatment of cancer. This chart shows a high cost per employee, which is typical for R&D companies. The value is determined by the potential of its technology platform and pipeline of drug candidates.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631797865 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ADC Therapeutics (ADCT)
ADC Therapeutics (ADCT) is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers. They have an approved drug, Zynlonta. This chart shows the commercial viability of this complex technology. Earnings per employee (scientist, marketer) depend on sales of this drug.
%20Chart%20ADC%20Therapeutics%20(ADCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ADC-Therapeutics-ADCT&v=1772631797912 "Company Profit Per Employee (in thousands of dollars) Chart ADC Therapeutics (ADCT)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers. It has an approved drug, ZYNLONTA. This chart shows how effectively the company is monetizing this complex oncology drug. It serves as a benchmark for assessing the success of ADC Therapeutics' commercialization in the competitive field of hematology.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772631797928 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
ADC Therapeutics (ADCT) is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers. They have an approved drug, Zynlonta. This chart shows their commercial success. It reflects how much the sales revenue of this high-tech and expensive drug covers the enormous costs of R&D and staff (including oncology specialists).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631797958 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ADC Therapeutics (ADCT)
ADC Therapeutics is an oncology company developing a new class of drugs—antibody-drug conjugates. This chart shows the company's pipeline to market. Its high revenue per employee reflects sales of high-priced blood cancer drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ADC-Therapeutics-ADCT&v=1772631797971 "Sales chart per company employee ADC Therapeutics (ADCT)")
Sales per employee in the market segment - Cancer blood
ADC Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for cancer treatment. This chart shows the average revenue per employee in the segment. It demonstrates the productivity of their R&D platform and commercial efforts (for approved drugs) compared to competitors.
Sales per employee for the market as a whole
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs)—"smart bombs" for the treatment of cancer (primarily lymphoma). They have approved products. This metric reflects how their R&D and sales teams generate high revenue from these complex, targeted oncology drugs.
Short shares by company, segment and market as a whole
Shares shorted by company ADC Therapeutics (ADCT)
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for cancer treatment. The bearish sentiment seen in this chart may be due to concerns about the side effects of its drugs or the intense competition in the hot ADC sector, dominated by giants.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ADC-Therapeutics-ADCT&v=1772631798099 "Short Shares Chart for the Company ADC Therapeutics (ADCT)")
Shares shorted by market segment - Cancer blood
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers (lymphoma). This chart reflects the overall sentiment in the sector. It reflects the high investor skepticism toward oncology companies operating in a highly competitive market where they must prove superiority over existing therapies.
Shares shorted by the overall market
ADC Therapeutics (ADCT) is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of blood cancers. This is a promising but highly competitive field. This chart is a barometer of market pessimism. When it's high, investors may sell ADCT shares, fearing their drugs won't hold up to the competition.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ADC Therapeutics (ADCT)
ADC Therapeutics develops antibody-drug conjugates (ADCs) for cancer treatment. This chart shows the stock's price momentum, which is highly sensitive to R&D news. A reading above 70 can reflect euphoria following positive clinical trial data or FDA approval, but it can also signal overbought conditions. A reading below 30 often reflects research setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ADC-Therapeutics-ADCT&v=1772631798194 "RSI 14 indicator chart for the company's stock ADC Therapeutics (ADCT)")
RSI 14 Market Segment - Cancer blood
ADC Therapeutics (ADCT) is a sniper in oncology. They create "smart bombs" (ADCs) that target blood cancers. The "Blood Cancer" sector (biotech) thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ADCT's rise a reaction to their Zynlonta trials, or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
ADC Therapeutics (ADCT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADCT (ADC Therapeutics)
ADC Therapeutics (ADCT) is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers. This chart shows the average target price. It reflects analysts' opinions on the commercial success of Zynlonta and the potential of other developments in the pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADCT-ADC-Therapeutics&v=1772631798288 "A chart showing analyst consensus forecasts for the expected stock price. ADCT (ADC Therapeutics)")
The difference between the consensus estimate and the actual stock price ADCT (ADC Therapeutics)
ADC Therapeutics (ADCT) is a Swiss biotech company, a leader in ADC (antibody-drug conjugate) technology. Its platform delivers a highly potent drug (PBD) precisely to cancer cells (focusing on blood cancers). This chart shows the difference between the consensus estimate and the price, reflecting analyst confidence in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADCT-ADC-Therapeutics&v=1772631798317 "A chart showing the difference between the consensus forecast and the actual stock price. ADCT (ADC Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
ADC Therapeutics (ADCT) is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers. Its drug, Zynlonta, is approved for lymphoma. This chart shows overall expectations for the blood cancer sector. It reflects whether experts believe ADC technology is a "magic bullet" for cancer.
Analysts' consensus forecast for the overall market share price
ADC Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for the treatment of blood cancers (lymphomas). These are "smart bombs" that deliver chemicals to tumors. This chart shows overall market sentiment. For ADCT, operating in the competitive oncology field, it's important to understand how risk appetite (sentiment) influences their R&D. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ADC Therapeutics
ADC Therapeutics is a biotech company specializing in conjugates (ADCs). These are smart bombs: an antibody (that finds cancer) + a toxic payload (that kills it). They focus on blood cancers (lymphoma). This chart is a barometer of their technology. It likely reflects the sales growth rate of their approved drug (Zynlonta) and the market's confidence in their ADC R&D platform.
AKIMA Market Segment Index - Cancer blood
ADC Therapeutics (ADCT) is a clinical-stage biotech pioneering the development of next-generation antibody-drug conjugates (ADCs) for the treatment of blood cancer (lymphoma). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does this breakthrough (ADC) R&D platform (ADCT) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
ADC Therapeutics is a pioneer in antibody-drug conjugates (ADCs) for the treatment of hematological cancers. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this commercial oncology platform.
